Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib and Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer
NCT05170594Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Dec 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluzoparib in ovarian cancer (3 arms), sponsored by Second Affiliated Hospital of Shandong First Medical University. Primary endpoint: Progression-Free-Survival at 2 years. Status: unknown.
02
Drugs
fluzoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05170594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170594.